Chickenpox
MONDO:0005700A contagious childhood disorder caused by the varicella zoster virus. It is transmitted via respiratory secretions and contact with chickenpox blister contents. It presents with a vesicular skin rash, usually associated with fever, headache, and myalgias. The pruritic fluid-filled vesicles occur 10-21 days after exposure and last for 3-4 days. An additional 3-4 days of malaise follows before the affected individual feels better. An individual is contagious 1-2 days prior to the appearance of the blisters until all blisters are crusted over. Generally, healthy individuals recover without complications.
Also known as: Varicella, chicken pox, chicken pox infection, chickenpox, varicella
30 clinical trials for this condition and its sub-types, 26 tagged with Chickenpox itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
MRNA vaccine takes on shingles: could it beat shingrix?
Vaccine OngoingThis early-stage trial is testing a new mRNA vaccine called ABO1108 to prevent shingles in adults aged 40 and above. Around 180 healthy volunteers will receive two shots of either the new vaccine at different doses, a placebo, or the existing Shingrix vaccine. The main goal is to…
Phase 1 • Sponsor: Suzhou Abogen Biosciences Co., Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 12:32 UTC
-
New mRNA shingles vaccine shows promise in Mid-Stage trial
Vaccine OngoingThis study tests a new mRNA vaccine called ABO1108 to see if it can prevent shingles in adults aged 40 and above. About 300 healthy volunteers will receive two shots, two months apart, and be compared to a placebo group. The goal is to measure the immune response and check for sa…
Phase 2 • Sponsor: Suzhou Abogen Biosciences Co., Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 12:31 UTC
-
New shingles vaccine candidate enters Mid-Stage trial
Vaccine OngoingThis study tests a new shingles vaccine called LYB004 in 840 adults aged 40 and older in China. Participants receive one of four different doses of the vaccine or a placebo. The goal is to see how well the vaccine triggers an immune response and whether it is safe.
Phase 2 • Sponsor: Guangzhou Patronus Biotech Co., Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 08:07 UTC
-
New shingles vaccine CRV-101 takes on shingrix in Head-to-Head trial
Vaccine OngoingThis phase 2 study tests a new shingles vaccine called CRV-101 (amezosvatein) against the current standard, Shingrix, in about 1,500 adults aged 50 and older. The goal is to see if CRV-101 is safer and triggers a strong immune response. Participants receive two shots and are moni…
Phase 2 • Sponsor: Curevo Inc • Aim: Vaccine
Last updated Jun 27, 2026 07:53 UTC
-
Engineered immune cells plus chickenpox vaccine take on childhood cancers
Disease control OngoingThis early-phase study tests a new treatment for advanced osteosarcoma and neuroblastoma that has not responded to standard therapy. Researchers take a patient's own immune cells (T cells), add a gene to help them recognize and attack cancer cells, and combine them with a chicken…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can a vaccine shield transplant patients from shingles?
Knowledge-focused OngoingThis study looks at how the immune system of kidney transplant patients responds to the shingles vaccine and to natural shingles infection. Researchers will track antibody and T-cell levels over time in patients who have had a transplant or are on the waiting list. The goal is to…
Sponsor: Susanne Dam Nielsen, MD, DMSc • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can immune cells predict herpesvirus danger in transplant patients?
Knowledge-focused OngoingThis study looks at how the immune system's T cells respond to two common herpesviruses—cytomegalovirus (CMV) and varicella-zoster virus (VZV)—in people who have had a liver transplant. Because transplant recipients take drugs that suppress their immune system to prevent organ re…
Sponsor: Susanne Dam Nielsen, MD, DMSc • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC